Universal API Implementation Guide - Local Development build (v1.1.20) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions

Release Q 42025

ANNOUNCEMENTS

• Gazyva for Immunology was approved by the FDA on 10/19/2025.
• Copay Enrollment for Gazyva for Immunology is available via UAPI as of 11/10/2025
• Enrollment for Access Solutions/Patient Foundation for Gazyva for Immunology via UAPI is currently not available. Enrollment via UAPI is projected to be ready early Q2 2026.
• Copay Questionnaire for Tecentriq and Tecentriq Hybreza indication for small cell lung cancer has been updated and is available as of 12/5/2025.
  
  

Copay Questionnaire Updates

Type	Release to Production	Available in QA (test) environment?	Product(s) impacted	linkId impacted (if applicable)	OLD	New	Comment
Update	12/5/2025	Yes	Tecentriq	linkId: tecentriq-fda-approved-indications	valueCoding.code: small-cell-lung-cancer valueCoding.display: Adults with a type of lung cancer called small cell lung cancer (SCLC). TECENTRIQ may be used with the chemotherapy medicines carboplatin and etoposide as your first treatment when your lung cancer: is a type called "extensive-stage small cell lung cancer," which means that it has spread or grown	valueCoding.code: small-cell-lung-cancer valueCoding.display: Adults with a type of lung cancer called "extensive stage small cell lung cancer (SCLC)", which is SCLC that has spread or grown: -TECENTRIQ may be used with the chemotherapy medicines carboplatin and etoposide as your first treatment -TECENTRIQ may be used with the medicine lurbinectedin as maintenance treatment when your lung cancer: has not progressed after first treatment with TECENTRIQ or atezolizumab and hyaluronidase-tqjs and the chemotherapy medicines carboplatin and etoposide	"small lung cancer" indication text change for Tecentriq
Update	12/5/2025	Yes	Tecentriq Hybreza	linkId: tecentriq-hybreza-fda-approved-indications	valueCoding.code: small-cell-lung-cancer valueCoding.display: Adults with a type of lung cancer called small cell lung cancer (SCLC). TECENTRIQ HYBREZA may be used with the chemotherapy medicines carboplatin and etoposide as your first treatment when your lung cancer: is a type called "extensive-stage small cell lung cancer," which means that it has spread or grown	valueCoding.code: small-cell-lung-cancer valueCoding.display: Adults with a type of lung cancer called "extensive stage small cell lung cancer (SCLC)", which is SCLC that has spread or grown: -TECENTRIQ HYBREZA may be used with the chemotherapy medicines carboplatin and etoposide as your first treatment -TECENTRIQ HYBREZA may be used with the medicine lurbinectedin when your lung cancer: has not progressed after first treatment with TECENTRIQ HYBREZA or atezolizumab and the chemotherapy medicines carboplatin and etoposide.	"small lung cancer" indication text change for Tecentriq Hybreza
Update	12/12/2025	Yes	All Products	linkId: 18-years-or-older	text: "Is the patient 18 years of age or older"	text: "Is the patient 18 years of age or older, or does the patient have a legal guardian 18 years of age or older to manage the program?"	update text to include LAP reference
Update	12/12/2025	Yes	All Products	linkId: residence-state	"answerOption": "valueString": "GU (Guam)", "valueString": "MP (Northern Mariana Islands)", "valueString": "PR (Puerto Rico)", "valueString": "VI (Virgin Islands)"	"answerOption": "valueString": "GU", "valueString": "MP", "valueString": "PR", "valueString": "VI"	remove descriptions after 2 character US territory